Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019
Headlines have led to outside-the-box thinking as well as a more global perspective in preventing CV disease and events.
Related Articles
Quick Takes: Cian McCarthy on Cardiac Biomarker Testing in the Emergency Department
Troponin testing is overused in some EDs and underused in others. Cian McCarthy, MB, BCh, explains why this needs to change.
TITRATE-HF: Use of GDMT for HF Is Getting Better but Still Not Ideal
The observed treatment rates, which “absolutely can go higher,” wouldn’t be acceptable for serious cancers, Stephen Greene says.
Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI
A decade on, there’s less revascularization with FFR-guided complete vs culprit only PCI, but COMPLETE-2 is on the way.
Immediate Multivessel PCI May Not Be So Bad in STEMI Patients With Shock: DanGer Data
Current guidelines support culprit-only PCI in these cases, but the “hypothesis-generating” results suggest taking a closer look.
Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI
A decade on, there’s less revascularization with FFR-guided complete vs culprit only PCI, but COMPLETE-2 is on the way.
No Additional Gain in Quality of Life With Dapagliflozin on Top of TAVI
The “somewhat unexpected” finding is likely related to the profound impact on health status from the procedure itself.
Whether Angio or CT Come First in Evaluating Chest Pain, QoL After Is Similar
A sex gap seen in quality of life deserves further scrutiny, but the DISCHARGE trial data are still reassuring, says Maros Ferencik.
May 2025 Dispatch for the CV Team
This month: shingles vaccine cuts CV events, brain injury impacts stroke risk, food insecurity’s health legacy, and more.